Skip to main content
PLOS One logoLink to PLOS One
. 2022 Apr 27;17(4):e0267322. doi: 10.1371/journal.pone.0267322

State-wide random seroprevalence survey of SARS-CoV-2 past infection in a southern US State, 2020

Victor M Cardenas 1,‡,*, Joshua L Kennedy 2,3,4,, Mark Williams 5, Wendy N Nembhard 1, Namvar Zohoori 1,6, Ruofei Du 7, Jing Jin 1,7, Danielle Boothe 1, Lori A Fischbach 1,8, Catherine Kirkpatrick 4, Zeel Modi 4, Katherine Caid 4, Shana Owens 4, J Craig Forrest 9, Laura James 2, Karl W Boehme 9,10, Ericka Olgaard 11, Stephanie F Gardner 12, Benjamin C Amick III 1,13
Editor: Maemu Petronella Gededzha14
PMCID: PMC9045671  PMID: 35476717

Abstract

The purpose of this cross-sectional study was to estimate the proportion of Arkansas residents who were infected with the SARS-CoV-2 virus between May and December 2020 and to assess the determinants of infection. To estimate seroprevalence, a state-wide population-based random-digit dial sample of non-institutionalized adults in Arkansas was surveyed. Exposures were age, sex, race/ethnicity, education, occupation, contact with infected persons, comorbidities, height, and weight. The outcome was past COVID-19 infection measured by serum antibody test. We found a prevalence of 15.1% (95% CI: 11.1%, 20.2%) by December 2020. Seropositivity was significantly elevated among participants who were non-Hispanic Black, Hispanic (prevalence ratio [PRs]:1.4 [95% CI: 0.8, 2.4] and 2.3 [95% CI: 1.3, 4.0], respectively), worked in high-demand essential services (PR: 2.5 [95% CI: 1.5, 4.1]), did not have a college degree (PR: 1.6 [95% CI: 1.0, 2.4]), had an infected household or extra-household contact (PRs: 4.7 [95% CI: 2.1, 10.1] and 2.6 [95% CI: 1.2, 5.7], respectively), and were contacted in November or December (PR: 3.6 [95% CI: 1.9, 6.9]). Our results indicate that by December 2020, one out six persons in Arkansas had a past SARS-CoV-2 infection.

Introduction

Serologic surveys assess the extent of viral infection at the population-level and can inform the decision-making process for returning to normal activities [1]. In the United States (US), most seroprevalence surveys of the SARS-Cov-2 virus, the etiologic agent of COVID-19, published by the date of submission, were conducted before October 2020 and in non-probability samples [218]. Of these, only seven used random sampling procedures so that every person in the target population had “a known, non-zero probability of being included in the sample” [19]. Only two of the seven studies [6, 7] were state-wide.

In this study, we expand on the small set of state-wide seroprevalence studies reporting results of a random sample serologic survey conducted in Arkansas, US. Arkansas has been among the southern states most affected by the fourth wave of the COVID-19 pandemic in the summer of 2021. We aimed to assess the proportion of the population susceptible to SARS-CoV-2 infection in a representative sample of the adult population in Arkansas in 2020, as opposed to those derived from convenience samples more likely affected by selection bias. Specifically, this study was conducted to 1) provide population-based estimates of prevalence of past infection with SARS-CoV-2 in Arkansas between May and December 2020, and 2) examine the association of age, sex, race/ethnicity, rural residence, contact with suspected infected persons, education, and occupation with past infection with SARS-CoV-2 as measured by IgG antibodies.

Materials and methods

Study design, study population and data collection

The Arkansas Coronavirus Antibodies Seroprevalence Survey (Arkansas CASS) data were collected as part of a larger survey conducted between May and December 2020. Our study is a cross-sectional study also referred to as a prevalence study [20]. The target population was the non-institutionalized adult population of the state. A random sample of the target was obtained as follows: potential participants were contacted using random digit dialing of mixed land line and targeted cell phone numbers in Arkansas. Land lines were a random sample of all known land lines in the state. Cell phone numbers were a random sample of active numbers used in Arkansas. Usage in the state was determined by call volume and location where a particular cell phone was used most. The mixed sample of land and cell phone numbers was purchased from a national company (Dynata Inc.) having access to these data and experience doing telephone polling in Arkansas. Samples of phone numbers were received from the company every two weeks.

To collect data, trained research assistants (RAs) called numbers from a list. If an eligible person answered the call, the RA explained that he/she was calling from a health science center and asked if the respondent was interested in answering questions about the COVID-19 pandemic. If the person refused to participate, the RA thanked him/her and proceeded to the next number. If the person reached was only Spanish speaking, an RA fluent in Spanish spoke with the respondent.

After expressing willingness to participate, the RA asked if the respondent was: 18 years or older, a resident of Arkansas, able to understand and speak English or Spanish. The willingness to go forward with the poll was used as implicit consent.

When a participant completed the poll, s/he was asked if s/he would be willing to participate in pandemic research. Those agreeing were informed about the study and, if they wished to continue, were scheduled for a blood draw and an interview. To collect a blood specimen, participants were given the choice of having a trained phlebotomist travel to his/her home (option chosen by 63.7%) or the participant could drive to a nearby local clinic (option chosen by 36.3%).

Participants were first provided the opportunity to consent then complete an interview and then the blood draw. All participants provided e-consent via the Research Electronic Data Capture system (REDCap v 11, Vanderbilt U, Nashville, TN) on a tablet. Interview responses were recorded using REDCap. The questionnaire collected data on age, sex, body weight, height, race/ethnicity, education, occupation, history of COVID-19-like illness, comorbidities, and contacts with persons who might have been infected with COVID-19.

Following interview completion, a 5 mL venous blood specimen was obtained. After completing the blood draw, participants received a $40 gift card. Specimens were collected in labelled clot activated sterile tubes, centrifuged, cold packed, and then shipped the same day to a dedicated central study laboratory using a courier service.

Measure of SARS-CoV-2 infection

The outcome variable was evidence of COVID-19 infection as measured by a positive clinical laboratory test. All sera were tested for IgG antibodies that target receptor binding domain of the spike protein 1 (S1) of the SARS CoV-2 using the Beckman Coulter DxI instrument (Brea, CA; Access SARS-CoV-2 IgG chemiluminescence immunoassay) in a CLIA certified clinical laboratory. In this automated instrument’s two-step immunoassay, the subjects’ serum samples were added to a mixture of buffer and paramagnetic particles coated with a recombinant SARS-CoV-2 spike protein specific to the S1 receptor binding domain. Following incubation, unbound protein is washed away, and anti-human IgG alkaline phosphatase conjugate monoclonal antibody is added. A second wash removes unbound conjugate. A chemilumiscent substrate is then added and the amount of light emitted is read using a luminometer. The Access SARS-CoV-2 IgG immunoassay has a sensitivity (Se) of 93.8% and specificity (Sp) of 100.0% [21].

Protection of human subjects

The protocol was reviewed and approved by the UAMS Institutional Review Board (Protocol 261232).

Data analysis

Potential selection bias was assessed comparing the proportions reporting that someone in their household may have had COVID-19 among those who declined to take part and those participating in the Arkansas CASS. We tested for group equivalence, within a margin of 2.5%, a difference that would be considered significant [22]. We used a raking procedure [23] in R (R Core Team, 2017) to obtain post-stratification weights, and computed final weights factoring the probabilities of selection based on age, sex, and race/ethnicity distribution of the state population [24].

We determined that a total sample a size of 1,500 subjects would be required to detect increases of at least twice a baseline prevalence level of 3% with a statistical power of >80%. For statistical analyses, we used the subpopulation of records with complete information on immunoassay, age, sex, and race/ethnicity (n = 1,565). We used Taylor series linearization estimators available in SUDAAN version 11 (RTI, Research Triangle Park: NC). We followed the ultimate cluster variance approach assuming sampling with replacement as described elsewhere [25]. The reciprocal of a respondent’s probability of selection or base weight was multiplied by the post-stratification raking weights to obtain the final sampling weights.

We estimated: 1) an 8-month point prevalence as the proportion of individuals with a past COVID-19 infection during the entire study period (i.e., [P^tMay,Dec=CtMay,DecNtMay,Dec], and 2) a two month point prevalence P^ti of COVID-19 infection as the proportion of infected among those specimens collected in November and December [26]. Observations were grouped by approximate month of collection into three groups: May-August, September-October, and November-December. Because of the potential for misclassification of the outcome due to imperfect sensitivity, the prevalence of COVID-19 was adjusted following recent recommendations [27].

The exposure variables were age (two categories 18–49, 50+ years), sex (male/female), race/ethnicity (non-Hispanic Whites [NHW], non-Hispanic Blacks [NHB], Hispanics, other), collection period (May-August, September-October, November-December), education (no college/college), rural/urban [28], contact with potential SARS-CoV-2 infected persons, number of persons in the household, and Standard Occupation Codes [29]. Occupations were grouped by title according to “essential” service, other occupations, and not working [18].

To obtain estimates of the association of SARS-CoV-2 infection, we estimated the prevalence ratios (PR) and 95% confidence intervals [30]. Unadjusted PRs were estimated for potential confounders, and stratified analyses assessed confounding and effect modification. Trends were assessed using the Cochran-Mantel-Haenszel test [31]. Adjusted prevalence ratios were estimated using predicted marginals from logistic regression [30]. All exposure variables were entered into multivariable models, but only those that meaningfully changed the crude estimates of other exposure variables and were significant at P ≤ 0.05 were included in the final model. Ordinal variables were treated as pseudo-continuous in the logistic regression models. The appropriateness of the multivariable logistic regression model was assessed using a Wald F Hosmer-Lemeshow goodness-of-fit test [32]. All analyses were conducted using SAS (v.9, Cary, NC) and SAS-callable SUDAAN (v. 11, RTI, NC).

The reporting of this study conforms to the STROBE statement [33].

Results

Comparison of respondents and non-respondents

There was no difference among participants and non-participants in the study regarding the proportion that knew or thought a member of the household was infected with SARS-CoV-2 (7.2% (95% CI: 6.7%, 7.9%) and 7.6% (95% CI: 6.4%, 9.0%)), respectively. The proportion of all potentially eligible participants taking part in the study was 56.3% (n = 1,696), and 1,565 were in the eligible population as described above. Differences between participants and non-participants were within ten percentage points for age, sex and race/ethnicity (S1 Table).

SARS-CoV-2 infection

During the 8-month data collection period, the overall prevalence of past COVID-19 infection was 7.1% (95% CI: 5.8%, 8.7%). The crude prevalence increased by a factor of 4.2 over time from 3.3% (95% CI: 1.9%, 5.9%) at the end of August to 14.2% (95% CI: 10.4%, 19.0%) at the end of December (Cochran-Mantel-Haenszel test for trend P-value <0.0001) (Table 1). Estimates of point prevalence by approximate month of collection are shown in Fig 1.

Table 1. Weighted period prevalence of SARS-CoV-2 past infection and prevalence ratios (PR) by select characteristics in a random sample of adults, Arkansas, May–December 2020.

Characteristics Past Infections N % Prevalence (95% CI) Crude PR (95% CI) Multivariable PR (95% CI)
All participants 107 1,565 7.1 (5.8, 8.7) == ==
TIME
Prevalence during
May-August 13 422 3.3 (1.9, 5.9) 1 (referent) 1 (referent)
September-October 50 801 6.2 (4.6, 8.4) 1.9 (1.0, 3.6) 1.8 (1.0, 3.4)
November-December 44 342 14.2 (10.4, 19.0) 4.2 (2.2, 8.1) 3.6 (1.9, 6.9)
Total 107 1,565 *P < 0.0001 *P = 0.0001
PERSON
Age (yrs.)
18–49 69 817 9.3 (7.2, 12.0) 2.0 (1.3, 3.0) 1.7 (1.1, 2.6)
50+ 38 748 4.7 (3.4, 6.4) 1 (referent) 1 (referent)
Total 107 1,565 P = 0.001 *P = 0.02
Sex
Female 74 989 8.2 (6.5, 10.4) 1.4 (0.9, 2.1) -
Male 33 576 6.0 (4.2, 8.5) 1 (referent) -
Total 107 1,565 P = 0.13
Race/Ethnicity
Non-Hispanic Whites 71 1,255 5.7 (4.4, 7.3) 1 (referent) 1 (referent)
Non-Hispanic Blacks 18 195 9.3 (5.7, 14.6) 1.6 (1.0, 2.8) 1.4 (0.8, 2.4)
Hispanics 15 91 17.6 (10.3, 28.3) 3.1 (1.7, 5.4) 2.3 (1.3, 4.0)
Other 3 24 11.5 (3.4, 32.3) 2.0 (0.6, 6.6) 2.3 (0.8, 6.8)
Total 107 1,565 P < 0.005 P < 0.05
Education
Without College 75 873 8.7 (6.9, 11.1) 1.8 (1.1, 2.7) 1.6 (1.0, 2.4)
College+ 32 689 5.0 (3.4, 7.2) 1 (referent) 1
Total 107 1,562 P < 0.01 P < 0.05
Occupation
High-demand essential services** 18 108 19.3 (11.9, 29.7) 2.8 (1.6, 4.9) 2.5 (1.5, 4.1)
Other workers 36 619 5.7 (4.0, 8.1) 0.8 (0.5, 1.3) 0.7 (0.4, 1.1)
Not working*** 53 838 6.8 (5.1, 9.1) 1 (referent) 1 (referent)
Total 107 1,565 P = 0.02 P = 0.0001
Any chronic disease
Yes 57 813 6.4 (4.9, 8.3) 0.8 (0.5, 1.2) -
No 50 752 7.9 (5.9, 10.6) 1 (referent) -
Total 107 1,565 P = 0.3
BMI category
Underweight (<18.5) 2 23 7.3 (1.7, 26.6) 1.3 (0.3, 5.7) -
Normal (18.5–24) 16 325 5.8 (3.3, 8.3) 1 (referent) -
Overweight (25–29) 27 426 7.0 (4.7, 10.5) 1.2 (0.6, 2.4) -
Obese I (30–34) 27 347 8.1 (5.5, 11.9) 1.4 (0.7, 2.7) -
Obese II (35–39) 16 219 7.0 (4.1, 11.8) 1.2 (0.6, 2.6) -
Obese III (40+) 19 225 8.0 (5.0, 12.6) 1.4 (0.7, 2.8) -
Total 107 1,565 P = 0.9
PLACE
Urban/Rural Residence
Rural 44 509 8.6 (6.3, 11.6) 1.4 (0.9, 2.1) -
Urban 57 992 6.2 (4.7, 8.2) 1 (referent) -
Total 101 1,501 P = 0.2
Region
Northwest 29 461 7.1 (4.8, 10.3) 1.2 (0.7, 2.1) -
Northeast 24 249 7.8 (5.2, 11.7) 1.4 (0.8, 2.4) -
Central 28 580 5.7 (3.8, 8.4) 1 (referent) -
Southwest 13 96 13.6 (7.6, 23.3) 2.4 (1.2, 4.7) -
Southeast 7 115 6.1 (2.8, 13.1) 1.1 (0.4, 2,6) -
Total 101 1,501 P = 0.2
Income of Zip Code of residence
(USD in thousands)
1st. tertile (18–36) 49 535 8.9 (6.6, 12.0) 1.8 (1.1, 3.0) -
2nd. tertile (37–46) 27 468 6.8 (4.5, 10.1) 1.4 (0.8, 2.5) -
3rd. tertile (47+) 25 498 4.4 (2.6, 6.2) 1 (referent) -
Total 101 1,501 *P = 0.02
Contact with someone known to have SARS-CoV-2 infection
Yes, within household 12 41 29.3 (16.6, 46.3) 6.6 (3.1, 14.1) 4.7 (2.1, 10.1)
Yes, outside household 16 128 13.1 (7.8, 21.3) 2.9 (1.4, 6.2) 2.6 (1.2, 5.7)
No, household size 1+ 66 1,128 6.3 (4.9, 8.2) 1.4 (0.8, 2.6) 1.4 (0.7, 2.6)
No and living alone 13 263 4.4 (2.5, 7.7) 1 (referent) 1 (referent)
Total 101 1,561 *P < 0.001 *P < 0.0005

All P-values of categorical variables are derived from Chi square F Wald tests except when noted

(*) where the P-value is from a Cochran-Mantel F Wald test for trend treating the variable as ordinal.

** Medical assistants, Childcare workers, Personal care aids, Nursing assistants, Police and Sheriff’s Patrol Officers, Registered Nurses, Lifeguards, Ski Patrol, and Other Recreational Protective Service Workers.

***Unpaid work including Homemakers, Retirees, Insufficient information.

†3, 64, and 5 records missing data on education, zip code of residence or rural/urban residence and household size, respectively. These records were retained as a separate category not shown

==Variable not included in the final model

Fig 1. Prevalence of SARS-CoV-2 infection in adults by date of collection, Arkansas, May—December 2020.

Fig 1

After adjusting the May to December period prevalence for imperfect sensitivity, the estimate increased slightly from 7.1% to 7.6% (95% CI: 6.2%-9.3%). The corresponding misclassification-adjusted prevalence for November-December increased from 14.2% to 15.1% (95% CI: 11.1%, 20.2%). The adjusted prevalence represents 348,000 adults in Arkansas ever infected.

Risk factors for SARS-CoV-2 past infection

Unadjusted results showed the 8-month prevalence of COVID-19 infection was higher among the young, minorities, particularly Hispanics, lower education, low income, high-risk occupation, South-West region of the state, and self-reported contact with an infected person in the same household (Table 1). There were no differences by sex, body mass index, or self-reported chronic disease. Also, an unadjusted comparison found an association with living in a larger household.

The multivariable analyses showed having contact with an infected person in the same household increased the prevalence of infection by almost 5-fold (PR = 4.7; 95% CI: 2.1, 10.1), over twice the prevalence by contact with an infected person outside the household (PR = 2.6; 95% CI: 1.2, 5.7). Increased prevalence was also found for November-December (PR = 3.6; 95% CI: 1.9, 6.9) and fall months for data collection (PR = 1.8; 95% CI: 1.0, 3.4) compared to the summer. Increased prevalence was also found for work in an essential occupation (PR: 2.5; 95% CI:1.5, 4.1), less than a college education (PR = 1.6; 95% CI: 1.0, 2.4), younger age (PR = 1.7; 95% CI: 1.1, 2.6) and race/ethnicity (PRs 1.4 and 2.3 for NH-Blacks, and Hispanics, respectively). The Hosmer Lemeshow F-goodness of fit test indicated the model fit the data well (P-value = 0.2).

Discussion

The study used data from a state-wide probability sample with an acceptable response rate and a clear case-definition. In multivariable analyses, we found COVID-19 infection was associated with race/ethnicity, affecting disproportionately Blacks and Hispanics. Additionally, persons with lower education, who worked in an essential occupation, had contact with an infected person inside the household, or had contact with an infected person outside the household were more likely to be seropositive. The analyses also showed a four-fold increase in COVID-19 prevalence from the first two months in which data were collected to November/December. The imperfect sensitivity adjusted estimate of infection by early December indicates 348,000 infections in adults, or 183,000 more than identified through testing in the state. The difference is considerably lower than results reported by Angulo et al. [34], based on earlier US surveys. The difference between surveys in other states and ours may reflect the increased testing capacity in Arkansas during the second half of 2020. Our prevalence point estimate is considerably higher than estimates achieved using a survey of residual bloods from healthcare clinics in Arkansas (9.2%, 95% CI = 7.2%, 11.1%) [35]. Our finding provides some support to the notion that convenience samples are more likely to be influenced by selection bias than population-based samples.

Our study found race/ethnicity was associated with higher COVID-19 infection. Higher infections among Hispanics and Blacks have been documented in several cross-sectional US studies [58, 18]. The prevalence of SARS-CoV-2 infection for Arkansans working in an occupation categorized as high-risk was three-times the prevalence of infection for Arkansans working in other occupations. However, essential workers in Arkansas had almost three-times the prevalence of infection compared to those not working.

The relation between race/ethnicity, occupation, and socioeconomic status requires further exploration. The distribution of essential workers by race/ethnicity may explain to some degree the observed racial and ethnic associations [36].

Our findings highlight the significant role of household contacts, as well as non-household contacts, in SARS-CoV-2 infection. Our results suggest that greater focus should be placed on household spread. This finding is particularly troubling as children and young adults have returned to school. The nature of the transmission can be better characterized using cohort studies of households [37, 38]. A study conducted in Guangzhou, the most populated city in southern China, found larger secondary attack rates among household contacts of a primary infectious case (16%-24%), than among non-household contacts (7%-9%) [38]. Our findings are also consistent with those studies conducted using a national US sample [10], and a sample collected in New York City [18].

This study is subject to several limitations including the number of and potential misclassification of exposures. Although infections represent only new occurrences since the start of the pandemic, the cross-sectional design could be affected by temporal ambiguity when assessing the role of some risk factors, such as occupation. Because of limited recall of contact with persons with SARS-CoV-2 infections, or lack of information on the number of bedrooms per household to appropriately assess crowding, or assigning income based on zip code of residence, there might be some unknown degree of measurement error for some exposure variables. The study findings may not be generalizable to the entire population as it did not include children nor high-risk institutionalized populations (e.g., prisons, nursing homes).

In summary, the level of humoral natural immunity acquired through infection in a US, mostly rural, southern state by December 2020, before the COVID-19 vaccination started, was 15.1%, In addition, by July 4, 2021, 1,064,000 adults [39] or only 46% of the population of the State, was fully vaccinated. This study informed the public and state health authorities that the population of Arkansas remained mostly susceptible (i.e., 85%, or 100%– 15%) to SARS-CoV-2 infection by the end of 2020. The introduction of more transmissible strains such as the Delta variant (B.1.617.2) [40] by the summer of 2021 with vaccination primarily targeting high-risk groups largely explains the fourth wave experienced at the time of the submission of this manuscript.

Supporting information

S1 Table. Comparison of characteristics of participants and non-participants, in a random sample of adults, Arkansas, May–December 2020.

(DOCX)

S2 Table. 2020 Arkansas Coronavirus Antibodies Seroprevalence Survey public dataset.

The analytic dataset of the 2020 ARCASS and data dictionary is available in the following doi: Cardenas, Victor (2022): public.csv. figshare. Dataset and dictionary. https://doi.org/10.6084/m9.figshare.19119524.v1.

(DOCX)

S1 File

(XLS)

S1 Checklist

(DOCX)

Acknowledgments

We thank Marianne Kouassi, BS, Ryan Mann, BS, and Hoda Hagrass, MD, PhD, from the University of Arkansas for Medical Sciences for their help with performing the Close reactions Beckman Access SARS-CoV-2 IgG chemiluminescence immunoassay. We also thank the Dynata, ExamOne and AFMC and their staff for their support to carry out the survey.

Data Availability

All analytic de-identified files are available https://doi.org/10.6084/m9.figshare.19119524.

Funding Statement

The work was supported through a research contract agreement with the Arkansas Department of Health with funding from the 2020 Coronavirus Relief Fund - CARES Act (VMC, LAF and LJ -PIs of record) and by grant UL1 TR003107 from the National Center for Advancing Translational Sciences (NCATS) (LJ -PI).” In addition, we state that “(T)he funders had no role in study design, data collection and analysis, the decision to publish, or preparation of the manuscript.

References

  • 1.Angulo FJ, Finelli L, Swerdlow DL. Reopening Society and the Need for Real-Time Assessment of COVID-19 at the Community Level. JAMA. 2020. Jun 9;323(22):2247–2248. doi: 10.1001/jama.2020.7872 . [DOI] [PubMed] [Google Scholar]
  • 2.Appa A, Takahashi S, Rodriguez-Barraquer I, Chamie G, Sawyer A, Duarte E, et al. Universal PCR and antibody testing demonstrate little to no transmission of SARS-CoV-2 in a rural community. Open Forum Infect Dis. 2020. Oct 30;8(1): ofaa531, doi: 10.1093/ofid/ofaa531 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Feehan AK, Velasco C, Fort D, Burton JH, Price-Haywood EG, Katzmarzyk PT, et al. Racial and workplace disparities in seroprevalence of SARS-CoV-2, Baton Rouge, Louisiana, USA. Emerg Infect Dis. 2021:314–3177. doi: 10.3201/eid2701.203808 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Feehan AK, Fort D, Garcia-Diaz J, Price-Haywood EG, Velasco C, Sapp E, et al. Seroprevalence of SARS-CoV-2 and Infection Fatality Ratio, Orleans and Jefferson Parishes, Louisiana, USA, May 2020. Emerg Infect Dis. 2020; 26: 2766–2769. doi: 10.3201/eid2611.203029 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Biggs HM, Harris JB, Breakwell L, Dahlgren FS, Abedi GR, Szablewski CM, et al. Estimated community seroprevalence of SARS-CoV-2 antibodies—two Georgia counties, April 28-May 3, 2020. MMWR Morb Mortal Wkly Rep. 2020. Jul 24;69(29):965–970. doi: 10.15585/mmwr.mm6929e2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Menachemi N, Yiannoutsos CT, Dixon BE, Duszynski TJ, Fadel WF, Wools-Kaloustian KK, et al. Population point prevalence of SARS-CoV-2 infection based on a statewide random sample—Indiana, April 25–29, 2020. MMWR Morb Mortal Wkly Rep. 2020. Jul 2469(29):960–964. doi: 10.15585/mmwr.mm6929e1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Chan PA, King E, Xu Y, Goedel W, Lasher L, Vargas M, et al. Seroprevalence of SARS-CoV-2 antibodies in Rhode Island from a statewide random sample. Am J Public Health. 2021. Apr;111(4):700–703. doi: 10.2105/AJPH.2020.306115 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Bruckner TA, Parker DM, Bartell SM, Vieira VM, Khan S, Noymer A, et al. Estimated seroprevalence of SARS-CoV-2 antibodies among adults in Orange County, California. Sci Rep. 2021. Feb 4;11(1):3081 doi: 10.1038/s41598-021-82662-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Demonbreun AR, McDade TW, Pesce L, Vaught LA, Reiser NL, Bogdanovic E, et al. Patterns and persistence of SARS-CoV-2 IgG antibodies in Chicago to monitor COVID-19 exposure. JCI Insight. 2021. May 10;6(9):e146148. doi: 10.1172/jci.insight.146148 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Nash D, Rane M, Chang M, Kulkarni SG, Zimba R, You W, et al. SARS-CoV-2 incidence and risk factors in a national, community-based prospective cohort of U.S. adults. medRxiv [Preprint]. 2021 Oct 12:2021.02.12.21251659. available from: https://www.medrxiv.org/content/10.1101/2021.02.12.21251659v2.
  • 11.Stout RL, Rigatti SJ. Seroprevalence of SARS-CoV-2 Antibodies in the US Adult asymptomatic population as of September 30, 2020. JAMA Netw Open. 2021. Mar 1;4(3):e211552. doi: 10.1001/jamanetworkopen.2021.1552 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Santarelli A, Lalitsasivimol D, Bartholomew N, Reid S, Reid J, Lyon C, et al. The seroprevalence of SARS-CoV-2 in a rural southwest community. J Osteopath Med. 2021. Feb 1;121(2):199–210. doi: 10.1515/jom-2020-0287 [DOI] [PubMed] [Google Scholar]
  • 13.McLaughlin CC, Doll MK, Morrison KT, McLaughlin WL, O’Connor T, Sholukh AM, et al. High community SARS-CoV-2 antibody seroprevalence in a ski resort community, Blaine County, Idaho, US. Preliminary Results. medRxiv [Preprint]. 2020 Jul 21:2020.07.19.20157198. doi: 10.1101/2020.07.19.20157198 [DOI]
  • 14.Bendavid E, Mulaney B, Sood N, Shah S, Bromley-Dulfano R, Lai C, et al. COVID-19 antibody seroprevalence in Santa Clara County, California. Int J Epidemiol. 2021. May 17;50(2):410–419. doi: 10.1093/ije/dyab010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Sood N, Simon P, Ebner P, Eichner D, Reynolds J, Bendavid E, et al. Seroprevalence of SARS-CoV-2-specific antibodies among adults in Los Angeles County, California, on April 10–11, 2020. JAMA. 2020; 323: 2425–2427. doi: 10.1001/jama.2020.8279 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Bryan A, Pepper G, Wener MH, Fink SL, Morishima C, Chaudhary A, et al. Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho. J Clin Microbiol. 2020. Jul 23;58(8):e00941–20. doi: 10.1128/JCM.00941-20 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Rosenberg ES, Tesoriero JM, Rosenthal EM, Chung R, Barranco MA, Styer LM, et al. Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York. Ann Epidemiol. 2020. Aug;48:23-29.e4. doi: 10.1016/j.annepidem.2020.06.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Pathela P, Crawley A, Weiss D, Maldin B, Cornell J, Purdin J, et al. Seroprevalence of SARS-CoV-2 following the largest initial epidemic wave in the United States: Findings from New York City, May 13-July 21, 2020. J Infect Dis. 2021. Jul 15;224(2):196–206. doi: 10.1093/infdis/jiab200 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Levy PS, Lemeshow S. Sampling of Populations: Methods and Applications, 4th ed. New York: Wiley; 2013. p. 17. [Google Scholar]
  • 20.Rothman KJ, Greenland S, Lash TL editors. Modern Epidemiology. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2008. p. 97. [Google Scholar]
  • 21.Lin YC, Lee YL, Cheng CY, Tseng WP, Wu JL, Lin CH, et al. Multicenter evaluation of four immunoassays for the performance of early diagnosis of COVID-19 and assessment of antibody responses of patients with pneumonia in Taiwan. Microbiol Immunol Infect. 2021. Oct;54(5):816–829. doi: 10.1016/j.jmii.2021.02.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987. Dec;15(6):657–80. doi: 10.1007/BF01068419 [DOI] [PubMed] [Google Scholar]
  • 23.Pasek J. Anesrake: ANES (American National Election Studies) Raking Implementation. R package version 0.80. April 28, 2018. https://CRAN.R-project.org/package=anesrake.
  • 24.U.S. Census Bureau, Population Division. Age, Sex, Race, and Hispanic Origin—6 race groups (SC-EST2019-ALLDATA6). [cited 2021 September 15, downloaded 2021 January 5]. Available from: https://www2.census.gov/programs-surveys/popest/tables/2010-2019/state/asrh/sc-est2019-alldata6.csv.
  • 25.Brogan DJ. Software for Sample Survey Data, Misuse of Standard Packages. In: Armitage P, Colton T. eds. Encyclopedia of Biostatistics. 2nd ed. Hoboken, NJ: Wiley InterScience,2005. doi: 10.1002/0470011815.b2a16072 [DOI] [Google Scholar]
  • 26.Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic Research. Principles and Quantitative Methods. New York: Van Nostrand Reinhold, 1982. p. 120. doi: 10.1210/jcem-55-4-787 [DOI] [Google Scholar]
  • 27.Sempos CT, Tian L. Adjusting Coronavirus Prevalence Estimates for Laboratory Test Kit Error. Am J Epidemiol. 2021. Jan 4;190(1):109–115. doi: 10.1093/aje/kwaa174 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.U.S. Office of Management and Budget, Bulletin No. 15–01, Revised Delineations of Metropolitan Statistical Areas, Micropolitan Statistical Areas, and Combined Statistical Areas, and Guidance on Uses of the Delineations of These Areas. [cited 2021 September 15]. Available from: https://www.whitehouse.gov/wp-content/uploads/legacy_drupal_files/omb/bulletins/2015/15-01.pdf.
  • 29.U.S. Centers for Disease Control and Prevention’s National Institute of Safety and Health. NIOSH Industry and Occupation Computerized Coding System. [cited 2021 September 15; downloaded 2021 January 5]. Available from https://csams.cdc.gov/nioccs/.
  • 30.Bieler GS, Brown GG, Williams RL, Brogan DJ. Estimating model-adjusted risks, risk differences, and risk ratios from complex survey data. Am J Epidemiol. 2010. Mar 1;171(5):618–23. doi: 10.1093/aje/kwp440 [DOI] [PubMed] [Google Scholar]
  • 31.Mantel N, Haenszel W. Statistical Aspects of the Analysis of Data from Retrospective Studies of Disease J Natl Cancer Inst. 1959. Apr;22(4):719–48. [PubMed] [Google Scholar]
  • 32.Shah BV, Barnwell BG. Hosmer-Lemeshow goodness of fit test for survey data. In Proceedings of the Joint Statistical Meetings—Section on Survey Research Methods. San Francisco, 2003. [Cited 2021 September 15] Available from: http://www.asasrms.org/Proceedings/y2003/Files/JSM2003-000744.pdf.
  • 33.Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration. PLoS Med. 2007. Oct 16;4(10):e297. doi: 10.1371/journal.pmed.0040297 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Angulo FJ, Finelli L, Swerdlow DL. Estimation of US SARS-CoV-2 Infections, Symptomatic Infections, Hospitalizations, and Deaths Using Seroprevalence Surveys. JAMA Netw Open. 2021. Jan 4;4(1):e2033706. doi: 10.1001/jamanetworkopen.2020.33706 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.U.S. Centers for Disease Control and Prevention. Nationwide Commercial Laboratory Seroprevalence Survey. [cited 2021 September 15]. Available from: https://covid.cdc.gov/covid-data-tracker/#national-lab.
  • 36.Webb Hooper M, Nápoles AM, Pérez-Stable EJ. COVID-19 and Racial/Ethnic Disparities. JAMA. 2020. Jun 23;323(24):2466–2467. doi: 10.1001/jama.2020.8598 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.He Z, Ren L, Yang J, Guo L, Feng L, Ma C, et al. Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study. Lancet. 2021. Mar 20;397(10279):1075–1084. 10.1016/s0140-6736(21)00238-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Jing QL, Liu MJ, Zhang ZB, Fang LQ, Yuan J, Zhang AR, et al. Household secondary attack rate of COVID-19 and associated determinants in Guangzhou, China: a retrospective cohort study. Lancet Infect Dis. 2020. Oct;20(10):1141–1150. 10.1016/s1473-3099(20)30471-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.U. S. Centers for Disease Control and Prevention. COVID-19 Data Tracker, Trends in Number of COVID-19 Vaccinations in the US. [cited 2021 September 15]. Available from: https://covid.cdc.gov/covid-data-tracker/#vaccination-trends_vacctrends-fully-cum.
  • 40.Allen H, Vusirikala A, Flannagan J, Twohig KA, Zaidi A, Chudasama D, et al. Household transmission of COVID-19 cases associated with SARS-CoV-2 delta variant (B.1.617.2): national case-control study. Lancet Reg Health Eur. 2022. Jan;12:100252. doi: 10.1016/j.lanepe.2021.100252 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Maemu Petronella Gededzha

24 Jan 2022

PONE-D-21-30543State-wide random seroprevalence survey of SARS-CoV-2 past infection in a southern US State, 2020PLOS ONE

Dear Prof Dr. Cardenas,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

The manuscript in the present form demands a revision before it can be published, so we suggests a “minor revision” of the paper

Please submit your revised manuscript by Mar 10 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Maemu Petronella Gededzha, Ph.D

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following financial disclosure: 

The work was supported through a research contract agreement with the Arkansas Department of Health with funding from the 2020 Coronavirus Relief Fund - CARES Act (VMC, LAF and LJ -PIs of record) and by grant UL1 TR003107 from the National Center for Advancing Translational Sciences (NCATS) (LJ -PI).

Please state what role the funders took in the study.  If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." 

If this statement is not correct you must amend it as needed. 

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

The work was supported through a research contract agreement with the Arkansas Department of Health with funding from the 2020 Coronavirus Relief Fund - CARES Act and by grant UL1 TR003107 from the National Center for Advancing Translational Sciences (NCATS). 

Please note that funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. 

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows: 

The work was supported through a research contract agreement with the Arkansas Department of Health with funding from the 2020 Coronavirus Relief Fund - CARES Act (VMC, LAF and LJ -PIs of record) and by grant UL1 TR003107 from the National Center for Advancing Translational Sciences (NCATS) (LJ -PI).

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

3. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

4. One of the noted authors is a group or consortium Arkansas Coronavirus Antibodies Seroprevalence Survey . In addition to naming the author group, please list the individual authors and affiliations within this group in the acknowledgments section of your manuscript. Please also indicate clearly a lead author for this group along with a contact email address.’  

5. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. 

6. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Additional Editor Comments:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming and body formatting. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Include page numbers and line numbers in the manuscript file. Use continuous line numbers.

3. Please ensure to read the PLOS ONE author’ s guidelines and make sure that references are reported in agreement with instruction of the journal.

4. On the data availability the author mentioned that some restrictions will apply, however they did not specify which restrictions and why?

5. Please amend your list of authors on the manuscript to ensure that each author contributions are linked to the symbols provided

6. Introduction-Sentence no 3, SARS-Cov-2 should be changed to SARS-CoV-2

7. Materials and method-Sentence ‘A random sample of the target was obtained as follows. Should’ read ‘A random sample of the target was obtained as follows:’

8. Be consistent with the use of sex vs gender through-out the manuscript.

9. Results-Please follow PLOS guidelines that to ensure that tables (including supplemental tables) and the reference are reported in agreement with instruction of the journal.

10. Page 12-remove Fig 1. Caption.

11. Reviewers 2 comments are indicated in the PDF document attached.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This study focused on estimating the number of Arkansans residents infected with SARS-CoV-2 between May and December 2020 and also to assess the determinants of infection. This was carried out by surveying the seroprevalence of, a statewide population-based random-digit dial sample of non-institutionalized adults in Arkansas. The outcome was past Covid-19 infection measured by serum antibody test . Notably, the seropositivity was significantly elevated among non-Hispanic black , Hispanic and

The method on how All sera were tested for IgG antibodies that target receptor binding domain of the spike protein of the SARS CoV-2 using the Beckman Coulter DxI instrument should be explained.

Major issues:

Overall, the data is promising, but the novelty of this study is relatively weak because the outcomes of the results obtained is not clearly explained.

Minor issues:

1. The introduction section needs to be worked on and be improved for example

Of these, only seven used random sampling procedures so that every person in the target population had “a known, non-zero probability of being included in the sample

A comma interferes with the flow.

The data obtained in this work are of interest for infectious disease specialists. The research was carried out using adequate methods and the manuscript may be published.

Reviewer #2: This was an important study and authors conducted it well.

Agreeing with the study's limitation of not including children. The study should have included children as they also play a crucial role in the transmission of SARS-CoV-2 infections; and it would have been nice to also learn if factors oberved in adults were also similar to those of children.

Authors should pay more attention to their references, consistency should be applied.

Manuscript should be checked for editorials and should also be checked by an English expect.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: Reviewer.pdf

Attachment

Submitted filename: PONE-D-21-30543 (1)_Plos One.pdf

Attachment

Submitted filename: Authorship statement (2).docx

PLoS One. 2022 Apr 27;17(4):e0267322. doi: 10.1371/journal.pone.0267322.r002

Author response to Decision Letter 0


7 Mar 2022

Re: PONE-D-21-30543

Title: State-wide random seroprevalence survey of SARS-CoV-2 past infection in a southern US State, 2020

Responses to Reviewer’s Comments and Suggestions

Reviewer 1

We would like to thank the reviewer for the valuable input and suggestions.

First point

This study focused on estimating the number of Arkansans residents infected with SARS-CoV-2 between May and December 2020 and also to assess the determinants of infection. This was carried out by surveying the seroprevalence of, a statewide population-based random-digit dial sample of non-institutionalized adults in Arkansas. The outcome was past Covid-19 infection measured by serum antibody test . Notably, the seropositivity was significantly elevated among non-Hispanic black , (and) Hispanic.

The method on how All sera were tested for IgG antibodies that target receptor binding domain of the spike protein of the SARS CoV-2 using the Beckman Coulter DxI instrument should be explained.

Response- We are very appreciative of the summary of this reviewer as it reflects the nature and importance of our study. We have tried to explain better the method used to test for the IgG antibodies to the RBD of the spike protein of the SARS-CoV-2.

We have added the following to the revised version:

“The outcome variable was evidence of COVID-19 infection as measured by a positive clinical laboratory test. All sera were tested for IgG antibodies that target receptor binding domain of the spike protein 1 (S1) of the SARS CoV-2 using the Beckman Coulter DxI instrument (Brea, CA; Access SARS-CoV-2 IgG chemiluminescence immunoassay) in a CLIA certified clinical laboratory. In this automated instrument’s two-step immunoassay, the subjects’ serum samples were added to a mixture of buffer and paramagnetic particles coated with a recombinant SARS-CoV-2 spike protein specific to the S1 receptor binding domain. Following incubation, unbound protein is washed away, and anti-human IgG alkaline phosphatase conjugate monoclonal antibody is added. A second wash removes unbound conjugate. A chemilumiscent substrate is then added and the amount of light emitted is read using a luminometer…”

Major Criticisms

Overall, the data is promising, but the novelty of this study is relatively weak because the outcomes of the results obtained is not clearly explained.

Response- As suggested, we have emphasized that non-random samples, for example, convenience samples are more likely to be affected by selection bias. By comparing our results with those of a survey of residual bloods from healthcare clinics in Arkansas we found significant differences: 9% of past infection in residual samples obtained in December 2020 versus 14% in our survey.

The revised text reads:

Introduction: “We aimed to assess the proportion of the population susceptible to SARS-CoV-2 infection in a representative sample of the adult population in Arkansas in 2020, as opposed to those derived from convenience samples more likely affected by selection bias.”

Discussion: “Our finding provides some support to the notion that convenience samples are more likely to be influenced by selection bias than population-based samples.”

“This study informed the public and state health authorities that the population of Arkansas remained mostly susceptible (i.e., 85%, or 100% – 15%) to SARS-CoV-2 infection by the end of 2020. The introduction of more transmissible strains such as the Delta variant (B.1.617.2) (40) by the summer of 2021 with vaccination primarily targeting high-risk groups largely explains the fourth wave experienced at the time of the submission of this manuscript.”

Minor issues:

1. The introduction section needs to be worked on and be improved for example

Of these, only seven used random sampling procedures so that every person in the target population had “a known, non-zero probability of being included in the sample

A comma interferes with the flow.

Response- The text is quoted from the textbook of Paul Levy and Stan Lemeshow, and the comma separates two items. The first is that the probability is known, and second the is not zero:

“a known, non-zero probability..” We thank you for the observation.

" The data obtained in this work are of interest for infectious disease specialists. The research was carried out using adequate methods and the manuscript may be published.

Response- Thanks for your comment.:

Reviewer 2

“This was an important study and authors conducted it well.”.

Response- We are thankful for comment.

Agreeing with the study's limitation of not including children. The study should have included children as they also play a crucial role in the transmission of SARS-CoV-2 infections; and it would have been nice to also learn if factors oberved in adults were also similar to those of children.

Response- We agree with the reviewer.

Authors should pay more attention to their references, consistency should be applied.

Response- We have checked for consistency and used the PLoS One guidelines.

Manuscript should be checked for editorials and should also be checked by an English expect.

Response- We have checked for potential spelling and grammar errors.

We have made all the changes to the format requested by the editors as well.

Attachment

Submitted filename: Point-by-pointResponsePLOSOneFebruary10.doc

Decision Letter 1

Maemu Petronella Gededzha

7 Apr 2022

State-wide random seroprevalence survey of SARS-CoV-2 past infection in a southern US State, 2020

PONE-D-21-30543R1

Dear Dr. Cardenas

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Maemu Petronella Gededzha, Ph.D

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: I am pleased with the responses to the questions, and with the final document. I am recommending the manuscript accepted for publication.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

Acceptance letter

Maemu Petronella Gededzha

13 Apr 2022

PONE-D-21-30543R1

State-wide random seroprevalence survey of SARS-CoV-2 past infection in a southern US State, 2020

Dear Dr. Cardenas:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Maemu Petronella Gededzha

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. Comparison of characteristics of participants and non-participants, in a random sample of adults, Arkansas, May–December 2020.

    (DOCX)

    S2 Table. 2020 Arkansas Coronavirus Antibodies Seroprevalence Survey public dataset.

    The analytic dataset of the 2020 ARCASS and data dictionary is available in the following doi: Cardenas, Victor (2022): public.csv. figshare. Dataset and dictionary. https://doi.org/10.6084/m9.figshare.19119524.v1.

    (DOCX)

    S1 File

    (XLS)

    S1 Checklist

    (DOCX)

    Attachment

    Submitted filename: Reviewer.pdf

    Attachment

    Submitted filename: PONE-D-21-30543 (1)_Plos One.pdf

    Attachment

    Submitted filename: Authorship statement (2).docx

    Attachment

    Submitted filename: Point-by-pointResponsePLOSOneFebruary10.doc

    Data Availability Statement

    All analytic de-identified files are available https://doi.org/10.6084/m9.figshare.19119524.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES